CD8A and melanoma: In addition, these monospecific anti-HLA-E mAbs may also represent a novel prognostic tool in patients with GI tumors or malignant melanoma and other metastasized cancers who plan to undergo immune cell (NK/NKT/CD8+ T cell)-based therapies by identifying which tumors/patients are most likely to respond.